文献速递先天性心脏病外科心外重症与机械循环支持

抗凝治疗与先天性心脏病新生儿围术期脑损伤风险

Anticoagulation therapy and the risk of perioperative brain injury in neonates with congenital heart disease.
PubMed 文献 · J Thorac Cardiovasc Surg · 2019-02-26

这项两中心观察性队列研究纳入118例足月新生儿(大动脉转位83例、单心室生理35例),比较抗凝与未抗凝者术后新发脑损伤。术前卒中者抗凝后新发硬膜下出血更多(36% vs 0%)。

要点

  • 抗凝未降低先心病新生儿围术期新发脑损伤风险
  • 单心室生理患儿抗凝者术后新发脑实质损伤更多
  • 术前卒中患儿抗凝后新发硬膜下出血更常见

核心结论

  • 在大动脉转位和单心室生理新生儿中,因术前卒中、术前血栓和/或BT分流而抗凝,未获得预防围术期新发脑损伤的预期获益。
  • 单心室生理患儿中抗凝与更多术后新发脑实质损伤相关,术前卒中患儿中抗凝与更多新发硬膜下出血相关。

研究设计与样本

  • 两中心观察性队列研究,纳入118例足月新生儿,其中大动脉转位83例、单心室生理35例。
  • 所有患儿均接受体外循环手术及术前、术后脑磁共振成像,并获取抗凝和抗血小板治疗详情。
  • 磁共振图像对卒中、白质损伤和出血进行评分,比较抗凝与未抗凝患儿的新发术后损伤。

主要发现

  • 118例中36例(29%)接受抗凝:11例(30%)因术前卒中,20例(56%)因术前外周/心内血栓,5例(14%)因BT分流。
  • 36例抗凝患儿中5例(14%)同时接受抗血小板治疗。
  • 两中心总体及大动脉转位患儿中,抗凝与未抗凝者新发术后损伤无差异。
  • 术前卒中患儿中,抗凝者新发硬膜下出血更多(36% vs 0%)。

临床怎么用

  • 对先心病新生儿因术前卒中、血栓或BT分流而常规抗凝的做法应谨慎,需个体化评估获益与风险。
  • 单心室生理患儿和术前卒中患儿抗凝时,应加强围术期脑损伤监测。

局限性

  • 为两中心观察性队列研究,样本量有限,抗凝组与非抗凝组基线可能不可比。
  • 原文未报告随机化或混杂因素校正细节,因果推断受限。
  • 作者指出需要严格的随机试验评估该人群抗凝治疗的安全性和有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: There is considerable variability in anticoagulation use in neonates with transposition of the great arteries (TGA) and single ventricle physiology (SVP) for secondary stroke prevention and primary cardiovascular indications. Leveraging cross-center differences in anticoagulation use, we compared the risk of new postoperative brain injury in neonates with TGA and SVP treated with anticoagulation relative to untreated neonates. METHODS: Two-center observational cohort study of 118 term-born neonates with TGA (n = 83) and SVP (n = 35), undergoing cardiopulmonary bypass surgery and pre- and postoperative brain magnetic resonance imaging. Anticoagulation and antiplatelet therapy details were obtained. Magnetic resonance images were scored for stroke, white matter injury, and hemorrhage. New postoperative injury was compared between neonates with and without anticoagulation for the 2-center cohort, and subsequently stratified by cardiac lesion type and anticoagulation indication. RESULTS: Thirty-six out of 118 neonates (29%) received anticoagulation: 11 (30%) for preoperative stroke, 20 (56%) for preoperative peripheral/intracardiac thrombus, and 5 (14%) for Blalock-Taussig shunt. Five out of 36 neonates (14%) treated with anticoagulation also received antiplatelet therapy. Although no differences were identified for the 2-center cohort or for neonates with TGA separately, significantly more new postoperative parenchymal brain injury (P = .04), particularly stroke, was found in SVP neonates with compared to without anticoagulation (31% vs 5%). In neonates who experienced preoperative stroke, new subdural hemorrhage (36% vs 0%) was more frequent in neonates treated with anticoagulation therapy compared with those without anticoagulation therapy. CONCLUSIONS: In our cohort of neonates with TGA and SVP, anticoagulation for preoperative stroke, preoperative thrombus, and/or Blalock-Taussig shunt did not have the anticipated benefit of preventing new perioperative brain injury. These findings indicate the critical need for rigorous randomized trials on the safety and effectiveness of anticoagulation therapy in this population.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Leijser LM, Chau V, Seed M, et al. Anticoagulation therapy and the risk of perioperative brain injury in neonates with congenital heart disease. J Thorac Cardiovasc Surg. 2019. PMID: 30981520. doi:10.1016/j.jtcvs.2019.02.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。